Solutions Ecosystems Reports Resources Data Pricing Login Book a demo
Power Law company profile

Lyell Immunopharma

Biotech & Life Sciences · San Francisco, United States · Founded 2018 · IPO 2021 Unicorn

A public taster of the full Dealroom platform — request a demo to explore live financials, founders, funding history, and market intelligence.

Valuation
$264M
Market cap · May/2026
Revenue
$36K
Latest reported FY
Featured in Unicorn$1B+ valuation tier · Power Law dataset 2026

Operator of a biotechnology company that develops cellular therapies to cure cancer

Investors

6 investors on Lyell Immunopharma's cap table

Sourced from Dealroom's funding history. Investor profile links are shown where available.

Series A 5 investors entered at this stage
8VC
ARCH Venture Partners
Sahsen Ventures
Bill & Melinda Gates Foundation
Arrive Roc Nation
Series B+ 1 investor entered at this stage
University of Washington

Global footprint

Where Lyell Immunopharma has talent and traffic

AI talent share
0.4% of workforce is AI talent
(1 of 226 staff)
Core AI00%
Other AI10.44%
Non-AI workforce22599.56%
Workforce by country
2 countries with
team presence
🇺🇸 United States99.9%
🇯🇵 Japan0.6%
2 countries shown
Web traffic by country
11K monthly visits
across markets
🇺🇸 United States78.2%
🇮🇳 India18.2%
🇭🇷 Croatia2.7%
🇩🇪 Germany1.8%
Top 4 markets shown

Patent intelligence

$5M patent portfolio · 30 active families

Estimated portfolio value
$5M
1.8% of market cap · 436.3× smaller than top peer Ablynx ($2B)
30 active patent families
Where Lyell Immunopharma innovates Molecular biologyIMMUNOLOGIC CELLSCell biologyPotassium ionsBiochemistry

Where Lyell Immunopharma concentrates vs peers

Each axis is a top-10 topic across Lyell Immunopharma and its closest peers. #1 = 100, #10 = 10, absent = 0.

Compare against

Source: Dealroom Patent Intelligence · Patsnap. Request a demo for the full per-sub-category breakdown, individual records, and quality-score history.

Capital deployed

Lyell Immunopharma's 6 investments and acquisitions.

Every disclosed deal where Lyell Immunopharma appeared as a backer or acquirer, 2020–2024. Toggle between venture rounds, M&A, or both. The map below is grouped by the target company's sector — the colored pill on each chip is the round type.

Portfolio analysis

6 deals across Lyell Immunopharma's capital deployment.

Where the deals concentrate by sector, stage, and decade.

By sectorCount
    By stageCount
      By periodCount

        01 · Deployment strategy vs peers

        Where Lyell Immunopharma deploys vs peers

        Each axis is a Dealroom topic tag — picked from the cluster's most-tagged themes. Values are normalized per axis: the peer with the highest tag-coverage on that axis sits at the edge, others scale relative to them. Toggle between M&A, venture, or both.

        Compare against

        02 · Portfolio market map

        Lyell Immunopharma's portfolio, mapped.

        Each chip is one company. Pill colour shows round type — green for Seed, blue for Series A, purple for B/C+, pink for late-stage, amber for M&A. Bigger sectors keep their full list behind “+ N more”.

        Stage
        Period
        6 of 6 deals

        Sentiment on X

        What X is saying about Lyell Immunopharma

        An AI-synthesized read of the highest-engagement posts about Lyell Immunopharma on X over the past 7 days. We rank by likes & retweets, ignore corporate channels, and surface the themes that broke out from real people.

        Reading the room on X — pulling top posts and synthesizing themes…

        Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour

        See Lyell Immunopharma on the full Dealroom platform

        Live deal flow, founder pedigree, hiring signals, revenue trajectory, and the full cap table.

        Book a demo Explore company profiles